Table III.
Characteristics and differences between treatment groups. P is calculated with a non-parametric Mann-Whitney test.
| Anti-IgE group n = 11 |
Anti-IL5 group n = 20 |
Anti-IL5R group n = 9 |
P | |
|---|---|---|---|---|
| Inhalant sensitisation | 11/11 (100%) | 12/20 (60%) | 8/9 (88.9%) | 0.196 |
| NSAID intolerance | 3/11 (27.2%) | 7/20 (35%) | 1/9 (11.1%) | 0.411 |
| CRSwNP | 9/11 (81.8%) | 17/20 (85%) | 7/9 (77.8%) | 0.892 |
| CRS onset | 0.818 | |||
| Early (< 40 y) Late (≥ 40 y) |
5/11 (45.4%) 6/11 (54.5%) |
11/20 (55%) 9/20 (45%) |
4/9 (44.4%) 5/9 (55.6%) |
|
| Asthma onset | 0.625 | |||
| Early (< 40 y) Late (≥ 40 y) |
4/11 (36.4%) 7/11 (63.6%) |
10/20 (50%) 10/20 (50%) |
3/9 (33.3%) 6/9 (66.7%) |
|
| Endoscopic sinus surgery | 7/11 (63.6%) | 15/20 (65%) | 8/9 (88.9%) | 0.431 |
| Chronic OCS therapy | 6/11 (54.5%) | 9/20 (45%) | 3/9 (33.3%) | 0.638 |
| Nasal steroid therapy | 5/11 (45.4%) | 14/20 (70%) | 7/9 (77.8%) | 0.258 |
NSAID: non-steroidal anti-inflammatory drugs; CRSwNP: chronic rhinosinusitis with nasal polyps; CRS: chronic rhinosinusitis; y: years old; OCS: oral corticosteroids